A phase II study of CCI-779 [temsirolimus] in combination with bevacizumab in stage III or IV melanoma.
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Bevacizumab (Primary) ; Temsirolimus (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 28 Jul 2016 Status changed from active, no longer recruiting to completed.
- 02 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.